MLYS
Mineralys Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 9 ▲ The FDA has accepted Mineralys Therapeutics' New Drug Application (N…
- Mar 12 ▲ Mineralys Therapeutics reported its fourth quarter and full-year 202…
- May 12 to May 18 ▼ 3 days of insider sells: $599.6K by 1 insider, avg $28.80
- Jun 10 to Jun 17 ▼ 4 days of insider sells: $631.2K by 2 insiders, avg $24.28
- Jun 26 to Jun 30 ▼ 2 days of insider sells: $4.7M by 2 insiders, avg $26.00
- Jul 9 to Jul 21 ▼ 5 days of insider sells: $1.1M by 3 insiders, avg $27.35
- Aug 10 ▼ 1 insider sell $58.8K at $27.09
- Aug 21 ▼ 1 insider sell $193.2K at $25.98
- Sep 15 to Sep 22 ▼ 3 days of insider sells: $3.3M by 3 insiders, avg $28.76
- Sep 30 ▼ 1 insider sell $1.9M at $25.46
- Oct 12 UBS initiates
- Nov 8 FDA: Mineralys Therapeutics Presents New Late-Breaking Data fro…
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $12.5M.
- InstitutionsBULLISH
Q3 2026: 24 added (2 new), 15 trimmed or exited.
- AnalystsBULLISH
14 of 17 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.632 → −$0.670 over 90 days. 0 up, 4 down in 30 days.
- Short sellersSTEADY
Short interest +3.4% to 7.69M shares. 5.0 days to cover, ≈8.7% of shares.
- TrendDOWNTREND
32% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| STATE STREET CORP | TRIM | $72.3M |
| Capital World Investors | ADD | $64.6M |
| Aberdeen Group plc | ADD | $23.4M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $16.4M |
| Qube Research & Technologies Ltd | DOUBLED | $15.3M |
| HRT FINANCIAL LP | DOUBLED | $10.1M |
| Nuveen, LLC | ADD | $9.3M |
| BARCLAYS PLC | DOUBLED | $4.6M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
17 analystsPrice is below the lowest target. Median implies +239%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 12, 2026 | UBS INITIATE | Neutral |
| Oct 12, 2026 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
COATS LONNEL Director Oct 19, 2026 | AWARD | 12,400 sh |
Peterson Kristine Director Oct 19, 2026 | AWARD | 12,400 sh |
COATS LONNEL Director Oct 19, 2026 | AWARD | 16,600 sh |
Peterson Kristine Director Oct 19, 2026 | AWARD | 16,600 sh |
Congleton Jon Chief Executive Officer Sep 30, 2026 | SELL | $1.9M |
Slingsby Brian Taylor Director Sep 22, 2026 | SELL | $3.0M |
Warren Eric Chief Commercial Officer Sep 21, 2026 | EXERCISE | $98.5K |
Warren Eric Chief Commercial Officer Sep 21, 2026 | SELL | $209.1K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.67 | -$0.73–-$0.59 | -13.3% | $0.00 |
| Next Q | -$0.81 | -$1.13–-$0.65 | -4.8% | $1.4M |
| Current FY | -$4.59 | -$4.82–-$4.26 | -3.7% | $0.00 |
| Next FY | -$2.60 | -$3.78–-$1.64 | -4.2% | $79.2M |
Short side
FINRA· Oct 30, 2026SecBot reports
27 filings · 8 press releases · 2 bullish · 2 bearish · 1 mixed · 22 neutral- BULLISH PRESS RELEASENov 8, 2026
Mineralys Therapeutics presented long-term data from the Transform-HTN open-label extension trial…
The sustained efficacy and safety data de-risks the upcoming PDUFA decision on December 22, 2026. Monitor the FDA advisory committee meeting (if any) and the final label for commercial potential.
- NEUTRAL 8-KNov 4, 2026
Mineralys Therapeutics reported Q3 2026 net loss of $57.3M, wider than the $36.9M loss in Q3 2025…
The PDUFA date on December 22, 2026 is the primary catalyst. Cash runway into 2028 covers launch. The $98.3M term loan adds leverage but extends runway. Monitor FDA decision and any advisory…
- NEUTRAL INST-CLUSTERNov 3, 2026
Three small asset managers added to their MLYS positions in Q3 2026, increasing aggregate holdings…
The cluster is too small to signal a shared thesis. Monitor next 13F for larger institutional moves or insider buying to confirm conviction.
- BULLISH 8-KOct 29, 2026
Mineralys Therapeutics terminated its License Agreement with Tanabe Pharma for lorundrostat and…
The full ownership of lorundrostat IP removes a key overhang and increases the strategic value of the asset, making Mineralys a more attractive M&A target or partnership candidate. Watch for any…
All MLYS filing & press-release reports (35)
- PRESS-RELEASE reportNov 8, 2026
- 8-K reportNov 4, 2026
- INST-CLUSTER reportNov 3, 2026
- 8-K reportOct 29, 2026
- PRESS-RELEASE reportOct 28, 2026
- 3 reportOct 20, 2026
- 3 reportOct 20, 2026
- 8-K reportOct 19, 2026
- 144 reportOct 13, 2026
- 144 reportSep 30, 2026
- PRESS-RELEASE reportSep 29, 2026
- CLUSTER reportSep 24, 2026
- CLUSTER reportSep 22, 2026
- 3 reportAug 12, 2026
- CLUSTER reportJul 23, 2026
- CLUSTER reportJul 20, 2026
- CLUSTER reportJul 15, 2026
- 144 reportJun 30, 2026
- 144 reportJun 29, 2026
- CLUSTER reportJun 17, 2026
- 144 reportJun 17, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportJun 3, 2026
- PRESS-RELEASE reportJun 3, 2026
- PRESS-RELEASE reportMay 30, 2026
- PRESS-RELEASE reportMay 18, 2026
- 144 reportMay 12, 2026
- 144 reportMay 11, 2026
- 144 reportApr 17, 2026
- CLUSTER reportApr 9, 2026
- 144 reportApr 13, 2026
- 144 reportApr 13, 2026
- DEFA14A reportApr 8, 2026
- PRESS-RELEASE reportMar 12, 2026
- PRESS-RELEASE reportMar 9, 2026